10-Q: Select Medical Holdings Reports Increased Revenue and Earnings in Q3 2024 Amidst Concentra Separation

Select Medical Holdings Corporation saw revenue and earnings growth in the third quarter of 2024, while also completing the initial public offering of its Concentra subsidiary.

Summary

• Select Medical Holdings Corporation reported a revenue of $1,761.2 million for the three months ended September 30, 2024, and $5,309.7 million for the nine months ended September 30, 2024.
• Net income for the three months ended September 30, 2024, was $81.0 million, and $292.9 million for the nine months ended September 30, 2024.
• The company completed the initial public offering (IPO) of Concentra on July 26, 2024, resulting in net proceeds of $516.4 million.
• Select Medical still owns 81.74% of Concentra's outstanding shares and intends to distribute the remaining equity interest to its stockholders within twelve months of the IPO.
• The company experienced a $10.9 million loss on early retirement of debt due to a prepayment on its term loan and an amendment to its credit agreement.
• The company's days sales outstanding was 55 days at September 30, 2024, compared to 52 days at December 31, 2023.
• The company's adjusted EBITDA was $205.5 million for the three months ended September 30, 2024, and $693.7 million for the nine months ended September 30, 2024.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with increased revenue and earnings, but also highlights some challenges such as increased debt and legal proceedings. The successful Concentra IPO is a significant positive, but the company still faces risks and uncertainties.

Positives

• The company experienced revenue growth across all segments.
• Net income and adjusted EBITDA increased year-over-year.
• The successful Concentra IPO generated significant capital for the company.
• The company reduced its debt through prepayments and repayments.
• The company's critical illness recovery hospital segment saw a 9.5% increase in adjusted EBITDA for the three months ended September 30, 2024.
• The company's rehabilitation hospital segment saw a 12.1% increase in adjusted EBITDA for the three months ended September 30, 2024.

Negatives

• The company incurred a $10.9 million loss on early retirement of debt.
• The company's outpatient rehabilitation segment saw a decrease in adjusted EBITDA for the nine months ended September 30, 2024.
• The company's days sales outstanding increased to 55 days at September 30, 2024, compared to 52 days at December 31, 2023.
• The company's cash flow from operations decreased year-over-year.

Risks

• The company is subject to interest rate risk on its variable rate debt.
• The company is subject to various legal actions and regulatory investigations.
• The company is subject to changes in government reimbursement policies.
• The company is subject to labor shortages and increased labor costs.
• The company is subject to cybersecurity risks and data breaches.
• The company is subject to the risk of not completing the distribution of its remaining equity interest in Concentra within twelve months of the IPO.

Future Outlook

Select Medical intends to distribute its remaining equity interest in Concentra to its stockholders within twelve months of the IPO. The company believes its internally generated cash flows and borrowing capacity will allow it to finance its operations in both the short and long term. The company may pursue opportunities to develop new joint venture relationships and open new outpatient rehabilitation clinics and occupational health centers. The company may also grow through opportunistic acquisitions.

Management Comments

• The company's management believes that the presentation of Adjusted EBITDA is important to investors because it is commonly used as an analytical indicator of performance by investors within the healthcare industry.
• Management uses Adjusted EBITDA to evaluate financial performance and determine resource allocation for each of the company's segments.

Industry Context

The healthcare industry is experiencing ongoing changes in reimbursement policies, labor costs, and regulatory requirements. Select Medical's performance is influenced by these factors, as well as the demand for its services in critical illness recovery, rehabilitation, outpatient care, and occupational health. The separation of Concentra reflects a strategic move to focus on core operations and potentially unlock value for shareholders.

Comparison to Industry Standards

• Select Medical's adjusted EBITDA margin of 11.7% for the three months ended September 30, 2024, is within the range of other large healthcare providers, but specific comparisons are difficult without detailed peer data.
• The company's revenue growth of 5.7% for the three months ended September 30, 2024, is comparable to other healthcare providers in the sector, but may vary based on specific service lines and geographic locations.
• The company's days sales outstanding of 55 days is within the range of other healthcare providers, but may be impacted by specific billing and collection processes.
• The company's debt levels are significant, but are being managed through repayments and refinancings, which is a common practice in the healthcare industry.

Legal Proceedings

• The company is involved in various legal actions, proceedings, and claims, including a qui tam lawsuit related to billing for physical therapy services.
• The company is cooperating with investigations by the Department of Justice, the California Department of Insurance, and other regulatory agencies.
• The company is facing class action lawsuits related to a data breach at a third-party vendor.

Stakeholder Impact

• Shareholders will benefit from the Concentra IPO and the potential distribution of remaining equity.
• Employees may be affected by changes in the company's structure and operations.
• Customers will continue to receive healthcare services from the company's various facilities.
• Suppliers may be affected by changes in the company's purchasing practices.
• Creditors will be affected by the company's debt management and repayment strategies.

Next Steps

• Select Medical intends to distribute its remaining equity interest in Concentra to its stockholders within twelve months of the IPO.
• The company will continue to monitor and manage its debt levels.
• The company will continue to pursue opportunities for growth through joint ventures, new facilities, and acquisitions.

Key Dates

Keywords

Select Medical Holdings, Concentra, IPO, healthcare, critical illness recovery, rehabilitation, outpatient, occupational health, financial results, EBITDA, revenue, net income, debt, Medicare, credit facilities